Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.
Type:
Grant
Filed:
September 9, 2010
Date of Patent:
August 20, 2013
Assignees:
Institut National de la Sante et de la Recherche Medicale, Commissariat a l'Energie Atomique, Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Inventors:
Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
Abstract: The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The conjugates exhibit an excellent macrophage stimulant action and do not require addition solutizing. They can be used in a wide range of applications, in particular for stimulating macrophages, for stimulating antibody synthesis, for combating infection, as an immunostimulant, in particular in relation to tumors, for preventing and treating septicaemic shock, for would healing and as an adjuvant for vaccines.
Type:
Grant
Filed:
July 18, 2003
Date of Patent:
January 8, 2008
Assignee:
GBF Gesellschaft fur Biotechnologische Forschung mbH
Abstract: The invention relates to a method for marker-free DNA expression cassette exchange in the genome of cells or parts of cells by using the FLP recombinase mediated cassette exchange. A first DNA expression cassette carrying a positive-negative selection marker flanked by two FLP recombinase recognition target (FRT) sites is integrated into a chromosomal locus of the genome. Following selection of cell clones surviving the conditions for positive selection, the first DNA cassette is exchanged by an incoming second DNA expression cassette located on a circular vector and carrying a transgene flanked by the same FRT sites as the first DNA cassette by using FLP-recombinase. The cell clones surviving the conditions for negative selection contain specifically inserted the gene of the incoming DNA cassette without inserted unwanted vector sequences or positive selectable markers.
Type:
Grant
Filed:
April 25, 2001
Date of Patent:
January 31, 2006
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Jürgen Bode, Jost Seibler, Dirk Schübeler
Abstract: Multicistronic expression units allow the equimolar expression of the genes located in the corresponding cistrons. These expression units are particularly suitable for the recombinant production of proteins composed of two or more polypeptide subunits.
Type:
Grant
Filed:
June 2, 1997
Date of Patent:
May 9, 2000
Assignees:
Beiersdorf AG, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Wilhelm Dirks, Manfred Wirth, Hansjorg Hauser, Wolfram Eichner, Volker Achterberg, Albrecht Dorschner, Wolfgang Meyer-Ingold, Heiko Mielke
Abstract: A single, unitary, solid phase support apparatus having a planar surface divided into a plurality of separate zone functions to detect antibodies. Each zone has bonded to it, a different peptide through its C-terminal end. The zones are incubated with the analyte sample and observed for reaction, indicating the virus-specific or bacteria specific presence or absence.
Type:
Grant
Filed:
September 30, 1996
Date of Patent:
November 3, 1998
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Abstract: The invention relates to a process for the production of a primer for consecutive DNA sequencing, in which at least two shortmers are hybridised adjacent to one another using a template and are then ligated with one another to form the primer, the process being characterised in that(a) a template in the form of a single strand of nucleotides is used in which the number of nucleotides is at least 6 and is not greater than approximately twice the total number of nucleotides of all the shortmers used, and(b) the primer formed is then separated from the template and from unreacted shortmers and recovered. The invention relates also to banks (libraries) of templates for the mentioned process.
Type:
Grant
Filed:
April 29, 1996
Date of Patent:
June 9, 1998
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Abstract: The invention relates to compounds which can be reacted with a carboxyl function with formation of an ester bond, whereby a protective group and, in particular, an anchor group for the carboxyl function is provided. The invention further relates to esters of acids which are obtainable by esterification with a compound according to the invention, and to the use of the compounds according to the invention in peptide synthesis.
Type:
Grant
Filed:
December 7, 1995
Date of Patent:
May 26, 1998
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH IGBF)
Abstract: The recombinant production of PDGF-AB in mammalian cells is disclosed by means of a bicistronic vector system in which an IRES sequence is located between the first and second cistrons and in which the B chain coding gene is located in the first cistron. The disclosed expression unit allows the equimolor expression of the A and B polypeptide chains.
Type:
Grant
Filed:
April 24, 1995
Date of Patent:
September 9, 1997
Assignees:
Beiersdorf AG, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Wolfram Eichner, Volker Achterberg, Albrecht Dorschner, Wolfgang Meyer-Ingold, Heiko Mielke, Wilhem Dirks, Manfred Wirth, Hansjorg Hauser
Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 22, 1997
Assignees:
Ciba-Geigy Corporation, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Gerhard H ofle, Norbert Bedorf, Edgar Forche, Klaus Gerth, Herbert Irschik, Rolf Jansen, Brigitte Kunze, Hans Reichenbach, Florenz Sasse, Heinrich Steinmetz, Wolfram Trowitzsch-Kienast, Johannes P. Pachlatko
Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
March 11, 1997
Assignees:
Ciba-Geigy Corporation, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Gerhard Hofle, Norbert Bedorf, Edgar Forche, Klaus Gerth, Herbert Irschik, Rolf Jansen, Brigitte Kunze, Hans Reichenbach, Florenz Sasse, Heinrich Steinmetz, Wolfram Trowitzsch-Kienast, Johannes P. Pachlatko
Abstract: The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 18, 1997
Assignees:
Ciba-Geigy Corporation, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Gerhard H ofle, Norbert Bedorf, Edgar Forche, Klaus Gerth, Herbert Irschik, Rolf Jansen, Brigitte Kunze, Hans Reichenbach, Florenz Sasse, Heinrich Steinmetz, Wolfram Trowitzsch-Kienast, Johannes P. Pachlatko
Abstract: A water-soluble protein conjugate modified by saccharides is covalently bound to a carbohydrate backbone via a saccharide group. Such protein conjugates modified by saccharides can be produced in a simple way by polymerizing a vinylsaccharide and conjugating in a known way the poly(vinylsaccharide) obtained in this way with the protein, which is preferably an enzyme. The protein conjugates according to the present invention are stable over long time periods at a high enzymatic activity and also in aqueous solution and are thus particularly suitable for use in test kits.
Type:
Grant
Filed:
April 4, 1991
Date of Patent:
January 2, 1996
Assignees:
Boehringer Mannheim GmbH, Gesellschaft fur Biotechnologische Forschung mbH
Inventors:
Wilhelm Tischer, Joachim Klein, Rolf-Joachim Muller, Stephan Engelke
Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.
Type:
Grant
Filed:
August 16, 1990
Date of Patent:
October 10, 1995
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Abstract: pPTH, bPTH or hPTH is modified by deletions from the natural C- and/or N-terminus. The modified compounds are useful active ingredients in therapeutic compositions. The therapeutic compositions do not stimulate renal adenylate cyclase but, rather, effect chondrocyte proliferation, that is to say, they exhibit a mitogenic and bone-specific effect.
Type:
Grant
Filed:
September 13, 1993
Date of Patent:
October 10, 1995
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Inventors:
Klaus-Dieter Schluter, Hubert Mayer, Edgar Wingender
Abstract: The invention relates to DNA sequences coding for PTH variants, to PTH variants, expression vectors, bacterial hosts, uses and therapeutic compositions.
Type:
Grant
Filed:
October 29, 1992
Date of Patent:
October 3, 1995
Assignee:
Gesellschaft fur Biotechnologische Forschung mbH (GBF)
Abstract: The invention relates to a method of preparing N.sup.6 -substituted NAD, NADP or FAD by Dimroth rearrangement, wherein the rearrangement is carried out without preceding reduction and subsequent reoxidation.
Type:
Grant
Filed:
January 24, 1990
Date of Patent:
March 21, 1995
Assignees:
Gesellschaft fur Biotechnologische Forschung mbH (GBF), Degussa AG